About: Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.65 (+3.11%)
ABOS NASDAQ Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc share price
ABOS price activity
Last Price
$2.650
Change (24hr)
0.08 USD (3.11%)
Volume
889.16K
Volume (4w avg)
-
Open
$2.55
Day Range
$2.52 - $2.67
Previous Close
$2.57
Last Trade
18 Sep, 8:22 pm GMT+0
Delayed
18 Sep, 8:22 pm GMT+0
ABOS price performance
Delayed
18 Sep, 8:22 pm GMT+0
ABOS Market Signals